Where I continue to disagree is that they have a fiduciary responsibility to us, their shareholders, and to expend hundreds of thousands of dollars on a hope and a prayer at this stage and in their current financially strapped position requires explanation. They do not have any remaining room in the shelf, and have already pushed the boundaries regarding appropriate use of the remaining shelf. That expenditure puts them at increased risk of bankruptcy, so my expectation is reasonable.
Additionally, they have no update to share regarding Direct which is appropriate at this time, and in that venue. They have provided sufficient visibility into manufacturing progress and any updates that they can provide could be done in a manner that does not cost us several hundred thousand dollars and risk embarrassment for the company and Dr. Linda Liau. Treating physicians could care less about manufacturing details, so any Flaskworks discussion is not appropriate for this audience as a substantive piece of that lecture.
The only reasonable expectation is discussion of results and/or regulatory status of Phase 3 DCvax-L in GBM. Anything else is a waste of critical resources at this time PERIOD.(Double entendre intended) June 4th ends the Quiet Period or stock crashes and lawsuits start to fly once again. Dropping below $0.38 per share paints September 12, 2020 in a very different light… and puts everyone associated with the company and presentations of data related to the trial in legal jeopardy.
June 4th has teeth IMHO
